82 results on '"S. Valmary-Degano"'
Search Results
2. In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial
- Author
-
O. Adotevi, Y. Godet, J. Galaine, Z. Lakkis, I. Idirene, J. M. Certoux, M. Jary, R. Loyon, C. Laheurte, S. Kim, A. Dormoy, F. Pouthier, C. Barisien, F. Fein, P. Tiberghien, X. Pivot, S. Valmary-Degano, C. Ferrand, P. Morel, E. Delabrousse, and C. Borg
- Subjects
adoptive cell transfer ,cetuximab ,intrahepatic infusion ,nk cell ,Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Despite successful introduction of NK-based cellular therapy in the treatment of myeloid leukemia, the potential use of NK alloreactivity in solid malignancies is still elusive. We performed a phase I clinical trial to assess the safety and efficacy of in situ delivery of allogeneic NK cells combined with cetuximab in liver metastasis of gastrointestinal origin. The conditioning chemotherapy was administrated before the allogeneic NK cells injection via hepatic artery. Three escalating doses were tested (3.106, 8.106 and 12.106 NK cells/kg) following by a high-dose interleukin-2 (IL-2). Cetuximab was administered intravenously every week for 7 weeks. Nine patients with liver metastases of colorectal or pancreatic cancers were included, three per dose level. Hepatic artery injection was successfully performed in all patients with no report of dose-limiting toxicity. Two patients had febrile aplasia requiring a short-term antibiotherapy. Grade 3/4 anemia and thrombopenia were also observed related to the chemotherapy. Objective clinical responses were documented in 3 patients and among them 2 occurred in patients injected with cell products harboring two KIR ligand mismatches and one in a patient with one KIR ligand mismatch. Immune monitoring revealed that most patients presented an increase but transient of IL-15 and IL-7 cytokines levels one week after chemotherapy. Furthermore, a high expansion of FoxP3+regulatory T cells and PD-1+ T cells was observed in all patients, related to IL-2 administration. Our results demonstrated that combining allogeneic NK cells transfer via intra-hepatic artery, cetuximab and a high-dose IL-2 is feasible, well tolerated and may result in clinical responses.
- Published
- 2018
- Full Text
- View/download PDF
3. La tumeur de Buschke Lowenstein chez la femme enceinte
- Author
-
S. Valmary-Degano, Pascale Hoffmann, C. Thong Vanh, A. Buisson, F. Istasse, T. Michy, and Didier Riethmuller
- Subjects
Gynecology ,medicine.medical_specialty ,Pregnancy ,Fetus ,Giant condyloma acuminatum ,Sexual transmission ,business.industry ,Obstetrics and Gynecology ,Disease ,medicine.disease ,Sex education ,Reproductive Medicine ,medicine ,Clinical case ,business ,After treatment - Abstract
Buschke Lownestein's tumour is a giant acuminate condyloma characterised by its degenerative potential, its invasive nature and its recurrence after treatment. It is a rare condition, transmitted mainly by sexual transmission and induced by to the human papillomavirus (HPV). The discussion will be illustrated by a clinical case The treatment is still under discussion but surgery seems to be the best option. Management during pregnancy is more complex since it must take into account the mother and her fetus. The delivery route is still debated. The post-treatment evolution was satisfactory and without recurrence until the delivery which, due to the antecedent of 3 caesarean sections, was carried out by cesarean section. HPV vaccination, sex education and early treatment of condyloma lesions should prevent and in any case improve the prognosis of this disease.
- Published
- 2022
- Full Text
- View/download PDF
4. Data Labeling Impact on Deep Learning Models in Digital Pathology: a Breast Cancer Case Study
- Author
-
K. Benaggoune, Z. Al Masry, C. Devalland, S. Valmary-degano, N. Zerhouni, and L. H. Mouss
- Published
- 2022
- Full Text
- View/download PDF
5. A unilateral nasal obstruction
- Author
-
S. Valmary-Degano, C. Fabre, and Christian Righini
- Subjects
medicine.medical_specialty ,Otorhinolaryngology ,business.industry ,medicine ,Humans ,Surgery ,Unilateral Nasal Obstruction ,Nasal Obstruction ,business - Published
- 2021
6. Une obstruction nasale unilatérale
- Author
-
C.-A. Righini, S. Valmary-Degano, and C. Fabre
- Subjects
Otorhinolaryngology ,Surgery - Published
- 2022
- Full Text
- View/download PDF
7. [Giant condyloma acuminatum in pregnancy]
- Author
-
D, Riethmuller, A, Buisson, C, Thong Vanh, F, Istasse, S, Valmary-Degano, T, Michy, and P, Hoffmann
- Subjects
Cesarean Section ,Condylomata Acuminata ,Pregnancy ,Humans ,Female ,Buschke-Lowenstein Tumor ,Papillomaviridae - Abstract
Buschke Lownestein's tumour is a giant acuminate condyloma characterised by its degenerative potential, its invasive nature and its recurrence after treatment. It is a rare condition, transmitted mainly by sexual transmission and induced by to the human papillomavirus (HPV). The discussion will be illustrated by a clinical case The treatment is still under discussion but surgery seems to be the best option. Management during pregnancy is more complex since it must take into account the mother and her fetus. The delivery route is still debated. The post-treatment evolution was satisfactory and without recurrence until the delivery which, due to the antecedent of 3 caesarean sections, was carried out by cesarean section. HPV vaccination, sex education and early treatment of condyloma lesions should prevent and in any case improve the prognosis of this disease.
- Published
- 2021
8. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin
- Author
-
J-B Delhorme, F Severac, G Averous, O Glehen, G Passot, N Bakrin, F Marchal, M Pocard, R Lo Dico, C Eveno, S Carrere, O Sgarbura, F Quenet, G Ferron, D Goéré, C Brigand, J Abba, K Abboud, M Alyami, C Arvieux, G Balagué, V Barrau, H Ben Rejeb, J-M Bereder, I Berton-Rigaud, F Bibeau, I Bonnefoy, D Bouzard, I Bricault, S Carrère, C de Chaisemartin, M Chassang, A Chevallier, T Courvoisier, P Dartigues, A Dohan, J Dubreuil, F Dumont, M Faruch-Bilfeld, J Fontaine, L Fournier, J Gagniere, D Geffroy, L Ghouti, F-N Gilly, L Gladieff, A Guibal, J-M Guilloit, F Guyon, B Heyd, C Hoeffel, C Hordonneau, S Isaac, P Jourdan-Enfer, R Kaci, R Kianmanesh, C Labbé-Devilliers, J Lacroix, B Lelong, A Leroux-Broussier, Y Lherm, G Lorimier, C Malhaire, P Mariani, E Mathiotte, P Meeus, E Mery, S Msika, C Nadeau, P Ortega-Deballon, O Pellet, P Peyrat, D Pezet, N Pirro, F Poizat, J Porcheron, A Poulet, P Rat, P Rousselot, P Rousset, H Senellart, M Serrano, V Servois, O Sgabura, A Skanjeti, M Svrcek, R Tetreau, E Thibaudeau, Y Touchefeu, J-J Tuech, S Valmary-Degano, D Vaudoyer, S Velasco, V Verriele-Beurrier, L Villeneuve, R Wernert, F Zinzindohoue, CHU Strasbourg, Les Hôptaux universitaires de Strasbourg (HUS), Department of Oncologic Surgery, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Department of oncologic surgery, Laboratoire de recherche en Hydrodynamique, Énergétique et Environnement Atmosphérique (LHEEA), École Centrale de Nantes (ECN)-Centre National de la Recherche Scientifique (CNRS), Carcinose Angiogenèse et Recherche Translationnelle, Angiogenese et recherche translationnelle (CART U965), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), CRLC Val d'Aurelle-Paul Lamarque, CRLCC Val d'Aurelle - Paul Lamarque, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Department of Surgical Oncology Institut Claudius Regaud, Department of Surgical Oncology, Université Paris-Sud - Paris 11 (UP11), and Département de chirurgie digestive
- Subjects
Male ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,Gastroenterology ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Pseudomyxoma peritonei ,Survival rate ,Peritoneal Neoplasms ,Survival analysis ,Urachus ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Cytoreduction Surgical Procedures ,Hyperthermia, Induced ,Middle Aged ,Prognosis ,Pseudomyxoma Peritonei ,medicine.disease ,Debulking ,Survival Analysis ,3. Good health ,medicine.anatomical_structure ,Appendiceal Neoplasms ,030220 oncology & carcinogenesis ,Peritoneal Cancer Index ,Female ,030211 gastroenterology & hepatology ,Surgery ,Hyperthermic intraperitoneal chemotherapy ,business - Abstract
BackgroundThe prognostic value of the primary neoplasm responsible for pseudomyxoma peritonei (PMP) remains poorly studied. The aim of this study was to determine the prognosis for patients with extra-appendicular PMP (EA-PMP) treated optimally with complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).MethodsAll patients treated for PMP with CCRS and HIPEC between 1994 and 2016 were selected retrospectively from a French multicentre database. Patients with EA-PMP had pathologically confirmed non-neoplastic appendices and were matched in a 1 : 4 ratio with patients treated for appendicular PMP (A-PMP), based on a propensity score.ResultsSome 726 patients were identified, of which 61 (EA-PMP group) were matched with 244 patients (A-PMP group). The origins of primary tumours in the EA-PMP group included the ovary (45 patients), colon (4), urachus (4), small bowel (1), pancreas (1) and unknown (6). The median peritoneal carcinomatosis index was comparable in EA-PMP and A-PMP groups (15·5 versus 18 respectively; P = 0·315). In-hospital mortality (3 versus 2·9 per cent; P = 1·000) and major morbidity 26 versus 25·0 per cent; P = 0·869) were also similar between the two groups. Median follow-up was 66·9 months. The 5-year overall survival rate was 87·8 (95 per cent c.i. 83·2 to 92·5) per cent in the A-PMP group and 87 (77 to 96) per cent in the EA-PMP group. The 5-year disease-free survival rate was 66·0 (58·7 to 73·4) per cent and 70 (53 to 83) per cent respectively.ConclusionOverall and disease-free survival following treatment with CCRS and HIPEC is similar in patients with pseudomyxoma peritonei of appendicular or extra-appendicular origin.
- Published
- 2018
- Full Text
- View/download PDF
9. Pseudopolyarthrite rhizomélique et paragangliome du nerf pneumogastrique
- Author
-
V. L’Huillier, L. Tavernier, O. Mauvais, and S. Valmary-Degano
- Subjects
030203 arthritis & rheumatology ,03 medical and health sciences ,0302 clinical medicine ,Otorhinolaryngology ,Surgery ,030223 otorhinolaryngology - Abstract
Resume Introduction Les paragangliomes du nerf vague sont des tumeurs rares. Ils sont le plus souvent asymptomatiques. Nous presentons un cas de paragangliome du nerf vague revele par une pseudopolyarthrite rhizomelique paraneoplasique et effectuons une revue de la litterature sur les paragangliomes cervicaux benins associes a un syndrome paraneoplasique. Cas clinique Un patient de 53 ans avait des symptomes de pseudopolyarthrite rhizomelique atypique. Dans le cadre du bilan, un syndrome tumoral est decouvert sur l’imagerie et le patient est opere par cervicotomie. L’examen histologique confirmait le diagnostic de paragangliome du nerf vague sans signe de malignite. Nous avons constate en postoperatoire une disparition rapide, complete et definitive des symptomes rhumatologiques. Nous avons donc conclu au diagnostic de pseudopolyarthrite rhizomelique paraneoplasique. Conclusion L’association d’un syndrome paraneoplasique et d’un paragangliome cervical reste exceptionnelle. Une mutation genetique predisposante doit etre systematiquement recherchee. Une surveillance au long cours doit etre realisee devant le risque de recidive locale, de nouvelle localisation ou de metastase.
- Published
- 2017
- Full Text
- View/download PDF
10. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study
- Author
-
S. Velasco, M. Chassang, Laurence Gladieff, Jean-Marc Guilloit, Frédéric Dumont, Thomas Courvoisier, Magali Svrcek, E. Mery, Jack Porcheron, Pablo Ortega-Deballon, V. Barrau, M. Serrano, Pierre Meeus, H. Senellart, Cécile Brigand, R. Kianmanesh, I. Bricault, M. Capovilla, O. Pellet, I. Bonnefoy, B. Lelong, A. Poulet, A. Chevallier, Delphine Vaudoyer, Frédéric Guyon, Julien Dubreuil, G. Ferron, S. Valmary-Degano, D. Geffroy, Franck Zinzindohoué, François-Noël Gilly, Laure Fournier, G. Lang Averous, Jean-Jacques Tuech, Catherine Arvieux, Karine Abboud, P. Rousselot, Y. Touchefeu, Guillaume Passot, R. Tetreau, Christine Hoeffel, Peggy Dartigues, Julio Abba, A. Dohan, Frédéric Bibeau, P. Peyrat, Naoual Bakrin, O. Sgabura, J.M. Bereder, Bruno Heyd, J. Lacroix, Frédéric Marchal, Johan Gagnière, Clarisse Eveno, J. Hommell-Fontaine, P. Rat, P. Jourdan-Enfer, C. Labbé-Devilliers, C. de Chaisemartin, Prudence Colpart, L. M'Hamdi, S. Carrere, Denis Pezet, D. Bouzard, R. Lo Dico, Marc Pocard, Gérard Lorimier, A. Leroux-Broussier, Cédric Nadeau, V. Verriele-Beurrier, François Quenet, Caroline Malhaire, S. Isaac, Nicolas Pirro, C. Hordonneau, Olivier Glehen, Clarisse Dromain, R. Kaci, L. Ghouti, E. Mathiotte, Vincent Servois, Mohammad Alyami, Pascale Mariani, H. Ben Rejeb, A. Guibal, S. Msika, Laurent Villeneuve, Romuald Wernert, F. Monnien, Diane Goéré, Emilie Thibaudeau, M. H. Laverrière, G. Balague, F. Poizat, M. Faruch-Bilfeld, Andrea Skanjeti, I. Berton-Rigaud, Yoann Lherm, Université Bourgogne Franche-Comté [COMUE] (UBFC), Pathology Department, CHU Besançon, Besançon, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Hospices Civils de Lyon, Departement de Neurologie (HCL), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de Hautepierre [Strasbourg], Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Paul Papin(Angers), Institut Bergonié [Bordeaux], UNICANCER, Department of Oncologic Surgery, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Departement of pathology, CHU Pontchaillou [Rennes], Service central de radiologie et d'imagerie médicale, CHU Grenoble-Hôpital Michallon, Gestes Medico-chirurgicaux Assistés par Ordinateur (TIMC-IMAG-GMCAO), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Département de chirurgie digestive, CHU Strasbourg, CRLC Val d'Aurelle-Paul Lamarque, CRLCC Val d'Aurelle - Paul Lamarque, Département de chirurgie digestive [Institut Paoli Calmettes], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Department of Radiology, Université Paris-Sud - Paris 11 (UP11), Laboratoire de Mécanique des Systèmes et des Procédés (LMSP), Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS), Carcinose Angiogenèse et Recherche Translationnelle, Angiogenese et recherche translationnelle (CART U965), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Surgical Oncology Institut Claudius Regaud, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Department of Surgical Oncology, Dept. of Nucl. Med., Jean Minjoz Univ. Hosp., Besancon, Centre Hospitalier Universitaire de Reims (CHU Reims), CRLCC René Gauducheau, Service de chirurgie thoracique cardiaque et vasculaire [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Center Paul Papin, Laboratoire de physique de la matière (LPM), Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de recherche en Hydrodynamique, Énergétique et Environnement Atmosphérique (LHEEA), École Centrale de Nantes (ECN)-Centre National de la Recherche Scientifique (CNRS), Institut Curie [Paris], Université de Lyon, Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Chirurgie Digestive, Cancérologique, Générale, Endocrinienne et Urgences (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Department of oncologic surgery, Department of nuclear Imaging, CHU Clermont-Ferrand, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service d'hépato-gastro-entérologie, CHU Saint-Etienne, Equipe Avenir. University of Burgundy, Univers, Transport, Interfaces, Nanostructures, Atmosphère et environnement, Molécules (UMR 6213) (UTINAM), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS), Service de Pathologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Sorbonne Université, Service d'Oncologie Médicale Thoracique et Digestive [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Médecine nucléaire, biophysique, isotopes [CHRU Besançon], Service de chirurgie thoracique cardiaque et vasculaire [Rennes] = Thoracic and Cardiovascular Surgery [Rennes], Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), and Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)
- Subjects
Male ,Mesothelioma ,PD-L1 ,Pathology ,medicine.medical_specialty ,Survival ,Antibodies, Neoplasm ,[SDV]Life Sciences [q-bio] ,B7-H1 Antigen ,Epithelioid subtype ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Biomarkers, Tumor ,medicine ,Humans ,Lymphocytes ,030212 general & internal medicine ,Peritoneal Neoplasms ,Retrospective Studies ,Immunity, Cellular ,biology ,business.industry ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Immunohistochemistry ,Peritoneal Malignant Mesothelioma ,3. Good health ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,biology.protein ,Peritoneal mesothelioma ,Biomarker (medicine) ,Female ,Surgery ,Hyperthermic intraperitoneal chemotherapy ,France ,Antibody ,business ,Follow-Up Studies - Abstract
Background Epithelioid peritoneal malignant mesothelioma (EPMM) is the most common subtype of this aggressive tumor. We compared two antibodies against PD-L1, a recent theranostic biomarker, and evaluated the prognostic value of PD-L1 expression by mesothelial and immune cells in EPMM. Methods Immunohistochemistry was performed on 45 EPMM. Clinical and pathological data were extracted from the RENAPE database. Using E1L3N and SP142 clones, inter-observer agreement, PD-L1 expression by mesothelial and immune cells and inter-antibody agreement were evaluated. The prognostic relevance of PD-L1 expression was evaluated in 39 EPMM by univariate and multivariate analysis of overall survival (OS) and progression-free survival (PFS). Results Inter-observer agreement on E1L3N immunostaining was moderate for mesothelial and immune cells, and fair for mesothelial and poor for immune cells using SP142. Using E1L3N, 31.1% of mesothelial and 15.6% of immune cells expressed PD-L1, and 22.2% of mesothelial and 26.7% of immune cells using SP142. Inter-antibody agreement was moderate. In most positive cases, 1–5% of tumor cells were positive. Using E1L3N, PD-L1 expression by lymphocytes was associated with better OS and PFS by both univariate and multivariate analysis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy predicted better prognosis than other treatments. Solid subtype was an independent prognostic factor for worse OS. Conclusion E1L3N appeared easier to use than SP142 to evaluate PD-L1 expression. A minority of EPMM expressed PD-L1, and only a few cells were positive. PD-L1 expression by immune cells evaluated with E1L3N was an independent prognostic factor in EPMM.
- Published
- 2017
- Full Text
- View/download PDF
11. Transfer of the lateral antebrachial cutaneous nerve to the dorsal branch of the ulnar nerve without nerve graft in case of lower brachial plexus injuries: Anatomical and feasibility study
- Author
-
U. Assouline, B. Constantinou, Laurent Obert, Julien Pauchot, S. Valmary-Degano, and D. Lepage
- Subjects
Male ,medicine.medical_specialty ,Context (language use) ,Sural nerve ,03 medical and health sciences ,0302 clinical medicine ,Cadaver ,Humans ,Medicine ,Brachial Plexus ,Orthopedics and Sports Medicine ,Brachial Plexus Neuropathies ,Ulnar nerve ,Nerve Transfer ,030222 orthopedics ,business.industry ,Magnetic resonance neurography ,Rehabilitation ,Ulna ,Anatomy ,medicine.disease ,Surgery ,medicine.anatomical_structure ,Brachial plexus injury ,Feasibility Studies ,Female ,business ,Brachial plexus ,030217 neurology & neurosurgery - Abstract
In the context of lower (C8–T1) brachial plexus injury, transfer of the lateral antebrachial cutaneous nerve (LABCN) to the dorsal branch of the ulnar nerve (DBUN) with an interposed sural nerve graft has been proposed to restore sensitivity on the ulnar side of the hand. The purpose of this study was to assess the feasibility of performing this transfer directly – without interposition of a nerve graft – by intraneural dissection of the DBUN. An anatomical study was performed with 20 upper limbs from adult human cadavers. The LABCN and the DBUN were dissected. The LABCN emerged from the lateral side of the biceps brachii muscle at an average of 2.6 ± 0.4 cm from the interepicondylar line and was 13.5 ± 2.6 cm long, on average. The DBUN arose from the ulnar nerve 8.2 ± 1.6 cm from the styloid process of the ulna. The maximum length of DBUN intraneural dissection relative to the ulnar nerve was 7.5 ± 2.1 cm, on average. The LABCN could be transferred to the DBUN in a tension-free manner with end-to-end suturing. Intraneural dissection of the DBUN allows LABCN nerve transfer without interposition of a graft.
- Published
- 2017
- Full Text
- View/download PDF
12. T1 Vertebra Pedicular Osteoid Osteoma: Minimally Invasive Surgical Resection Aided by New Integrated Navigation to 3D Imaging Device
- Author
-
S. Valmary-Degano, Gael Kerschbaumer, Marc Prod’homme, Jérôme Tonetti, Mehdi Boudissa, and Guillaume Cavalié
- Subjects
Surgical resection ,Osteoid osteoma ,030222 orthopedics ,medicine.medical_specialty ,business.industry ,Imaging guidance ,Tumor resection ,Case Report ,General Medicine ,medicine.disease ,Resection ,Vertebra ,lcsh:RD701-811 ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,lcsh:Orthopedic surgery ,medicine ,Operative time ,Radiology ,business ,030217 neurology & neurosurgery ,Fixation (histology) - Abstract
We hereby describe a minimally invasive resection of a T1 pedicular osteoid osteoma next to the vertebral canal. The patient had an 18-month report of painful radiculopathy. We performed the surgery under 3D imaging guidance using navigation with an all-in-one device. Full procedure irradiation was 1.17 mSv for a 181-picture acquisition. Complete operative time incision to closure was 58 minutes. Despite sparing the vertebral stability without any fixation, the tumor resection was well-margined, thanks to the focused guidance. After surgery, the patient had complete relief of his symptoms at the 6-month follow-up. 3D imaging system coupled to navigation made the procedure safe without consuming time. The single Surgivisio® device allows comfortable 3D minimally invasive spine navigation surgery with the ergonomics of a C-arm.
- Published
- 2019
13. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database
- Author
-
V. Kepenekian, D. Elias, G. Passot, E. Mery, D. Goere, D. Delroeux, F. Quenet, G. Ferron, D. Pezet, J.M. Guilloit, P. Meeus, M. Pocard, J.M. Bereder, K. Abboud, C. Arvieux, C. Brigand, F. Marchal, J.M. Classe, G. Lorimier, C. De Chaisemartin, F. Guyon, P. Mariani, P. Ortega-Deballon, S. Isaac, C. Maurice, F.N. Gilly, O. Glehen, G. Averous, F. Bibeau, D. Bouzard, A. Chevallier, S. Croce, P. Dartigues, S. Durand-Fontanier, L. Gouthi, B. Heyd, R. Kaci, R. Kianmanesh, M.H. Laverrière, E. Leblanc, B. Lelong, A. Leroux, V. Loi, C. Mariette, S. Msika, P. Peyrat, N. Pirro, J. Paineau, F. Poizat, J. Porcheron, P. Rat, J.M. Regimbeau, E. Thibaudeau, J.J. Tuech, S. Valmary-Degano, V. Verriele, P. Zerbib, and F. Zinzindohoue
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Population ,computer.software_genre ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,education ,Chemotherapy ,education.field_of_study ,Database ,business.industry ,Hazard ratio ,Retrospective cohort study ,Perioperative ,medicine.disease ,Confidence interval ,3. Good health ,030220 oncology & carcinogenesis ,Peritoneal mesothelioma ,030211 gastroenterology & hepatology ,Hyperthermic intraperitoneal chemotherapy ,business ,computer - Abstract
Purpose: Diffuse malignant peritoneal mesothelioma (DMPM) is a severe disease with mainly locoregional evolution. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is the reported treatment with the longest survival. The aim of this study was to evaluate the impact of perioperative systemic chemotherapy strategies on survival and postoperative outcomes in patients with DMPM treated with curative intent with CRS-HIPEC, using a multi-institutional database: the French RENAPE network. Patients and methods: From 1991 to 2014, 126 DMPM patients underwent CRS-HIPEC at 20 tertiary centres. The population was divided into four groups according to perioperative treatment: only neoadjuvant chemotherapy (NA), only adjuvant chemotherapy (ADJ), perioperative chemotherapy (PO) and no chemotherapy before or after CRS-HIPEC (NoC). Results: All groups (NA: n Z 42; ADJ: n Z 16; PO: n Z 16; NoC: n Z 48) were comparable regarding clinicopathological data and main DMPM prognostic factors. After a median follow-up of 61 months, the 5-year overall survival (OS) was 40%, 67%, 62% and 56% in NA, ADJ, PO and NoC groups, respectively (P Z 0.049). Major complications occurred for 41%, 45%, 35% and 41% of patients from NA, ADJ, PO and NoC groups, respectively (P Z 0.299). In multivariate analysis, NA was independently associated with worse OS (hazard ratio, 2.30; 95% confidence interval, 1.07e4.94; P Z 0.033). Conclusion: This retrospective study suggests that adjuvant chemotherapy may delay recurrence and improve survival and that NA may impact negatively the survival for patients with DMPM who underwent CRS-HIPEC with curative intent. Upfront CRS and HIPEC should be considered when achievable, waiting for stronger level of scientific evidence.
- Published
- 2016
- Full Text
- View/download PDF
14. Prise de décision en réunion de concertation pluridisciplinaire pour les polypes coliques dégénérés: étude qualitative rétrospective des comptes-rendus d'endoscopie et d'anatomopathologie sur une période de deux ans en région «Franche-Comté»
- Author
-
B Morel, S Valmary-Degano, and S Koch
- Subjects
business.industry ,Medicine ,business ,Humanities - Published
- 2018
- Full Text
- View/download PDF
15. Œdème vulvaire révélant une mastocytose systémique
- Author
-
P. Humbert, François Aubin, E. Daguindau, M. Girardin, F. Locatelli, S. Valmary-Degano, Fabien Pelletier, and E. Deveza
- Subjects
Dermatology - Abstract
Resume Introduction La mastocytose systemique est caracterisee par une proliferation anormale de mastocytes dans differents organes. Nous rapportons le cas original d’une mastocytose systemique revelee par un œdeme vulvaire. Observation Une femme de 24 ans consultait en dermatologie pour un œdeme vulvaire apparaissant au moment des rapports sexuels. Elle presentait des episodes vasomoteurs des membres inferieurs, une urticaire du tronc a l’effort, des diarrhees et des douleurs osseuses. Le bilan biologique montrait une tryptasemie a 29,7 μg/L et une histaminemie a deux fois la normale. Le myelogramme mettait en evidence une infiltration par des mastocytes dysmorphiques. La recherche de la mutation D816V du gene c-kit etait positive. Les biopsies duodenales revelaient des amas de mastocytes avec plus de 15 mastocytes agreges. L’immunomarquage CD2 etait non contributif et le CD25 non realise. Une osteopenie trabeculaire etait constatee. Nous avons pose le diagnostic de mastocytose systemique indolente (ISM variant Ia) d’apres les criteres OMS 2008. Un traitement symptomatique a ete instaure (anti-histaminiques anti-H1 et anti-H2, antileucotrienes), ainsi qu’un suivi clinicobiologique. Discussion Les symptomes qui ont conduit ici au diagnostic de mastocytose systemique avec atteinte de plusieurs organes etaient des signes cutanes qui pouvaient paraitre mineurs, lies a la degranulation mastocytaire. Il s’agit du troisieme cas decrit de mastocytose revelee par un œdeme vulvaire et du premier cas revelant une atteinte systemique. Les deux cas precedemment decrits avaient revele une mastocytose cutanee pure. La mastocytose, systemique ou cutanee, doit faire partie des diagnostics differentiels a evoquer devant un œdeme vulvaire.
- Published
- 2015
- Full Text
- View/download PDF
16. In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial
- Author
-
Idir Idirene, S. Valmary-Degano, Eric Delabrousse, C. Barisien, Christophe Ferrand, Yann Godet, Romain Loyon, Olivier Adotevi, Fabienne Pouthier, Jeanne Galaine, Francine Fein, Christophe Borg, A. Dormoy, Pierre Tiberghien, P. Morel, Caroline Laheurte, Zaher Lakkis, Stefano Kim, Xavier Pivot, Jean-Marie Certoux, and Marine Jary
- Subjects
lcsh:Immunologic diseases. Allergy ,0301 basic medicine ,medicine.medical_specialty ,Adoptive cell transfer ,medicine.medical_treatment ,Immunology ,Phases of clinical research ,lcsh:RC254-282 ,Gastroenterology ,Natural killer cell ,Metastasis ,Cell therapy ,03 medical and health sciences ,Internal medicine ,cetuximab ,medicine ,Immunology and Allergy ,adoptive cell transfer ,Original Research ,Chemotherapy ,Cetuximab ,business.industry ,FOXP3 ,intrahepatic infusion ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,nk cell ,lcsh:RC581-607 ,business ,medicine.drug - Abstract
Despite successful introduction of NK-based cellular therapy in the treatment of myeloid leukemia, the potential use of NK alloreactivity in solid malignancies is still elusive. We performed a phase I clinical trial to assess the safety and efficacy of in situ delivery of allogeneic NK cells combined with cetuximab in liver metastasis of gastrointestinal origin. The conditioning chemotherapy was administrated before the allogeneic NK cells injection via hepatic artery. Three escalating doses were tested (3.10(6), 8.10(6) and 12.10(6) NK cells/kg) following by a high-dose interleukin-2 (IL-2). Cetuximab was administered intravenously every week for 7 weeks. Nine patients with liver metastases of colorectal or pancreatic cancers were included, three per dose level. Hepatic artery injection was successfully performed in all patients with no report of dose-limiting toxicity. Two patients had febrile aplasia requiring a short-term antibiotherapy. Grade 3/4 anemia and thrombopenia were also observed related to the chemotherapy. Objective clinical responses were documented in 3 patients and among them 2 occurred in patients injected with cell products harboring two KIR ligand mismatches and one in a patient with one KIR ligand mismatch. Immune monitoring revealed that most patients presented an increase but transient of IL-15 and IL-7 cytokines levels one week after chemotherapy. Furthermore, a high expansion of FoxP3(+)regulatory T cells and PD-1(+) T cells was observed in all patients, related to IL-2 administration. Our results demonstrated that combining allogeneic NK cells transfer via intra-hepatic artery, cetuximab and a high-dose IL-2 is feasible, well tolerated and may result in clinical responses.
- Published
- 2017
17. Polymyalgia rheumatica and vagal paraganglioma
- Author
-
O. Mauvais, V. L’Huillier, L. Tavernier, and S. Valmary-Degano
- Subjects
musculoskeletal diseases ,Male ,Vagus Nerve Diseases ,Pathology ,medicine.medical_specialty ,Gene mutation ,Asymptomatic ,Metastasis ,Polymyalgia rheumatica ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,Paraganglioma ,medicine ,Humans ,Cranial Nerve Neoplasms ,skin and connective tissue diseases ,030223 otorhinolaryngology ,Head and neck ,Vagal paraganglioma ,Histological examination ,Paraganglioma, Extra-Adrenal ,business.industry ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Treatment Outcome ,Otorhinolaryngology ,Polymyalgia Rheumatica ,030220 oncology & carcinogenesis ,Surgery ,medicine.symptom ,business - Abstract
Introduction Vagal paraganglioma are rare tumors that are mostly asymptomatic. We report a case of vagal paraganglioma associated with paraneoplastic polymyalgia rheumatica and review the literature on benign paragangliomas of the head and neck associated with paraneoplastic syndrome. Case report A 53-year-old man presented with atypical polymyalgia rheumatica. MRI revealed a tumor that was then surgically excised. Histological examination confirmed the diagnosis of benign vagal paraganglioma. Rapid, complete and permanent resolution of all rheumatological symptoms were observed postoperatively, confirming the diagnosis of paraneoplastic polymyalgia rheumatica. Conclusion Paraganglioma of the neck associated with paraneoplastic syndrome remains exceptional. A predisposing gene mutation must be systematically investigated. Long-term surveillance must be ensured due to the risk of local recurrence, second tumors or metastasis.
- Published
- 2017
18. Mucinous Neoplasms Of The Appendix And Peritoneum: Virtual Microscopy For Histomorphologic Assessment And Interobserver Diagnostic Reproducibility
- Author
-
I. Villa, L. Villeneuve, N. J. Carr, S. Isaac, O. Glehen, M. Capovilla, A. Chevallier, S. Croce, R. Kaci, G. Lang-Averous, M.-H. Laverriere, A. Leroux-Broussier, E. Mery, F. Poizat, S. Valmary-Degano, V. Verriele-Beurrier, F.-N. Gilly, F. Bibeau, and P. Dartigues
- Subjects
lcsh:R5-920 ,lcsh:Medical technology ,lcsh:R855-855.5 ,lcsh:R858-859.7 ,lcsh:Medicine (General) ,lcsh:Computer applications to medicine. Medical informatics - Abstract
Introduction/ Background Among gastrointestinal (GI) tumours, pseudomyxoma peritonei (PMP) from appendiceal origin has unique clinical and morphologic features. Due to the relative paucity of patients and the absence of therapeutic consensus, evaluation and refinement of the morphologic criteria used for assessment of the disease are still difficult. As a result, a uniformly accepted classification is still lacking. In collaboration with NJ Carr, who initiated the conference consensus process, in Basingstoke, and on behalf of the French group RENA-PATH, 11 experienced GI pathologists agreed to participate to a virtual workshop, in order to assess inter-observer variability in PMP diagnosis and staging. Aims The goal of the study was to evaluate, for appendiceal and peritoneal mucinous neoplasms, the degree of concordance in the identification of diagnostic histological criteria by experienced pathologists, and to assess the degree of inter-individual variation in the application of WHO classification (2010) and TNM staging system (7th edition). Methods A single section stained with hematoxylin and eosin from 9 resected cases of mucinous neoplasms was selected by members of RENA-PATH. All digitalized at a maximum resolution (X40) using an HAMMAMATSU scanner system, to ensure that all participants evaluate exactly the same tumour areas; 1 to 16 questions were prepared for each case. On Teleslide web platform, interactive services provided by TRIBVN. All submitted cases were then reviewed by a panel of 11 pathologists with specific expertise and interest in PMP. Data were analyzed using SAS program. Results Whole slide set evaluated by all participants; no abstention or “unknown diagnosis” for any submitted case. Agreement for classification, WHO 2010: • Appendiceal mucinous neoplasms: LAMN 83 %; mucinous adenocarcinoma 92%. • Peritonei mucinous carcinoma: Low grade 91.7%; high grade 91.7%. • Disagreement on the concept of High Grade AMN defined by low power architecture of LAMN + high grade cytology. • Agreement for using pTNM classification (82%) in PMP. • Pushing Invasion (PI) and dissection by acellular mucin (DAM) in appendix wall are not reproducible criteria and need to be better defined. • Criteria need to be redefined to use HAMN according to a majority of participants. • The identification of signet ring cells is not reproducible; the lesion needs to be better defined. • Invasion of organs and pattern of invasion (broatfront invasion / classic by irregular glands or single cells with desmoplasia) are not reproducible criteria. • Improvement in staging assessment is needed Conclusion: Although histopathological features of peritoneal disease are significant prognostic factors requiring pathologists to classify mucinous carcinoma peritonei (pseudomyxoma peritonei), reproducibility in interpretation must be improved. This international collaborative project allows pathologists worldwide to share their expertise and knowledge through a dedicated interactive workshop session. It is expected an improvement in the management of mucinous neoplasms of the appendix and peritoneum., Diagnostic Pathology, Vol 1 No 8 (2016): 13. European Congress on Digital Pathology
- Published
- 2016
- Full Text
- View/download PDF
19. A new internet tool to report peritoneal malignancy extent. PeRitOneal MalIgnancy Stage Evaluation (PROMISE) application
- Author
-
François Quenet, Frédéric Marchal, François-Noël Gilly, Laurent Villeneuve, Jean-Marc Guilloit, M. Carretier, S. Carrere, Clarisse Eveno, Julien Fontaine, Faheez Mohamed, Delphine Vaudoyer, S. Isaac, A. Chevallier, A. Dohan, Cécile Brigand, P. Rousset, F. Poizat, Peggy Dartigues, Julio Abba, Frédéric Dumont, Nicolas Pirro, C. Petorin, Frédéric Guyon, G. Lang-Averous, S. Evrard, Gérard Lorimier, Karine Abboud, P. Rat, E. Mery, G. Pourcher, Jack Porcheron, Pablo Ortega-Deballon, M. Messager, Rea Lo Dico, Nicolas Goasguen, Pierre Meeus, R. Tetreau, Houda Ben Rejeb, S. Durand-Fontanier, P. Peyrat, A. Mariani, Dominique Elias, D. Bouzard, D. Geffroy, D. Delroeux, J.M. Bereder, C. de Chaisemartin, Christophe Mariette, R. Kianmanesh, Pierre-Jean Valette, Jean-Jacques Tuech, M. H. Laverrière, B. Lelong, Guillaume Piessen, C. Labbé, Mehdi Karoui, S. Velasco, Guillaume Passot, Diane Goéré, V. Barrau, G. Balague, V. Loi, Olivier Glehen, P. Rousselot, Jean-Marc Regimbeau, Emilie Thibaudeau, Thomas Courvoisier, V. Verriele-Beurrier, Frédéric Bibeau, G. Desolneux, M. Chassang, Marc Pocard, Magali Svrcek, Jérémie H. Lefevre, J. Lacroix, O. Fay, Franck Zinzindohoué, Catherine Arvieux, Naoual Bakrin, Denis Pezet, A. Leroux, Cédric Nadeau, Charles Sabbagh, Romuald Wernert, Bruno Heyd, Pascale Mariani, S. Msika, S. Valmary-Degano, L. Ghouti, A. Thivolet, Clarisse Dromain, R. Kaci, G. Ferron, Pôle Information Médicale Evaluation Recherche (IMER), Hospices Civils de Lyon (HCL), Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Département de chirurgie, CRLCC Val d'Aurelle - Paul Lamarque, and Département de radiothérapie
- Subjects
MESH: Medical Records ,medicine.medical_specialty ,Scoring application ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Medical Records ,Peritoneal malignancy ,03 medical and health sciences ,Peritoneal Neoplasm ,0302 clinical medicine ,MESH: Patient Care Team ,Predictive Value of Tests ,Medicine ,Resectability ,MESH: Peritoneal Neoplasms ,Humans ,Stage (cooking) ,Peritoneal Neoplasms ,Neoplasm Staging ,Patient Care Team ,Internet ,MESH: Humans ,business.industry ,Medical record ,MESH: Peritoneum ,Reproducibility of Results ,General Medicine ,MESH: Neoplasm Staging ,Peritoneal cancer index ,MESH: Predictive Value of Tests ,3. Good health ,Surgery ,MESH: Reproducibility of Results ,MESH: Internet ,Oncology ,030220 oncology & carcinogenesis ,Predictive value of tests ,Conventional PCI ,Peritoneal Cancer Index ,030211 gastroenterology & hepatology ,Radiology ,Peritoneal diseases ,Extent disease ,Peritoneum ,business ,Peritoneal carcinomatosis ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Based on the importance of assessing the true extent of peritoneal disease, PeRitOneal MalIgnancy Stage Evaluation (PROMISE) internet application (www.e-promise.org) has been developed to facilitate tabulation and automatically calculate surgically validated peritoneal cancer index (PCI), and other surgically validated scores as Gilly score, simplified peritoneal cancer index (SPCI), Fagotti and Fagotti-modified scores. This application offers computer-assistance to produce simple, quick but precise and standardized pre, intra and postoperative reports of the extent of peritoneal metastases and may help specialized and non-specialized institutions in their current practice but also facilitate research and multicentre studies on peritoneal surface malignancies.
- Published
- 2016
- Full Text
- View/download PDF
20. Early-life exposures to phenols, parabens and phthalates and fat mass at 3 years of age in the SEPAGES cohort.
- Author
-
Colombini M, Heude B, Lyon-Caen S, Thomsen C, Sakhi AK, Valmary-Degano S, Bayat S, Slama R, Philippat C, and Ouidir M
- Abstract
Background: Early-life exposure to short half-life chemicals may influence adiposity growth, a precursor to obesity. Previous studies often relied on limited urine samples that inadequately represent exposure during pregnancy or infancy. Additionally, childhood adiposity is commonly estimated using body mass index, which does not accurately reflect body composition. We aimed to investigate associations between early-life exposures to phenols, parabens, phthalates and fat mass percent at 3 years of age among 341 mother-child couple from the SEPAGES cohort. We further assessed potential effect modification by sex., Methods: We measured 8 phenols, 4 parabens, 13 phthalates and 2 non-phthalate plasticizer metabolites from weekly pooled urine sample collected from mothers during pregnancy (three urine samples a day, median 18 and 34 gestational weeks), and from their infant (one urine sample a day, at 2 and 12 months). Clinical examinations at 3 years included standardized skinfold thickness measurements and bioelectrical impedance analysis to calculate fat mass percentage., Results: Positive associations were identified between prenatal exposures to bisphenol S, mono-benzyl phthalate (MBzP), monoethyl phthalate (MEP), and mono-n-butyl phthalate and fat mass percentage at 3 years, while triclosan showed a negative association. MBzP and MEP showed effect modification by sex, with stronger associations among females. No significant associations were detected for postnatal exposures., Conclusion: This study suggests associations between prenatal exposures to short half-life chemicals and percent fat mass in preschool children. Furthermore, this study is the first investigating the impact of prenatal bisphenol S exposure, highlighting the need for investigation of this overlooked compound., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma.
- Author
-
Özoğul E, Montaner A, Pol M, Frigola G, Balagué O, Syrykh C, Bousquets-Muñoz P, Royo R, Fontaine J, Traverse-Glehen A, Bühler MM, Giudici L, Roncador M, Zenz T, Carras S, Valmary-Degano S, de Leval L, Bosch-Schips J, Climent F, Salmeron-Villalobos J, Bashiri M, Ruiz-Gaspà S, Costa D, Beà S, Salaverria I, Giné E, Quintanilla-Martinez L, Brousset P, Raffeld M, Jaffe ES, Puente XS, López C, Nadeu F, and Campo E
- Subjects
- Humans, Male, Female, Translocation, Genetic, Middle Aged, Aged, Chromosome Breakpoints, Genes, Immunoglobulin, Gene Rearrangement, V(D)J Recombination genetics, Lymphoma, Mantle-Cell genetics, Lymphoma, Mantle-Cell pathology, Cyclin D1 genetics, Lymphoma, Large B-Cell, Diffuse genetics
- Abstract
Mantle cell lymphoma (MCL) is genetically characterized by the IG::CCND1 translocation mediated by an aberrant V(D)J rearrangement. CCND1 translocations and overexpression have been identified in occasional aggressive B-cell lymphomas with unusual features for MCL. The mechanism generating CCND1 rearrangements in these tumors and their genomic profile are not known. We have reconstructed the IG::CCND1 translocations and the genomic profile of 13 SOX11-negative aggressive B-cell lymphomas using whole genome/exome and target sequencing. The mechanism behind the translocation was an aberrant V(D)J rearrangement in three tumors and by an anomalous IGH class-switch recombination (CSR) or somatic hypermutation (SHM) mechanism in ten. The tumors with a V(D)J-mediated translocation were two blastoid MCL and one high-grade B-cell lymphoma. None of them had a mutational profile suggestive of DLBCL. The ten tumors with CSR/SHM-mediated IGH::CCND1 were mainly large B-cell lymphomas, with mutated genes commonly seen in DLBCL and BCL6 rearrangements in 6. Two cases, which transformed from marginal zone lymphomas, carried mutations in KLF2, TNFAIP3 and KMT2D. These findings expand the spectrum of tumors carrying CCND1 rearrangement that may occur as a secondary event in DLBCL mediated by aberrant CSR/SHM and associated with a mutational profile different from that of MCL., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
22. [SMARCB1-deficient renal medullary carcinoma with revealed by a supra-clavicular metastatic lymph node].
- Author
-
Bendimerad MA, Meilhac-Fournier C, Nika E, Piolat C, Giovannini D, and Valmary-Degano S
- Subjects
- Humans, Adolescent, Male, Carcinoma, Medullary pathology, Carcinoma, Medullary genetics, Sickle Cell Trait complications, Clavicle pathology, Kidney Neoplasms pathology, Kidney Neoplasms genetics, Lymphatic Metastasis, SMARCB1 Protein deficiency, SMARCB1 Protein genetics
- Abstract
We report the case of a 14 year-old teenager who has SC hemoglobinosis and presented with a tumor syndrome with a retro-peritoneal mass, a supraclavicular lymph node and a mid-renal lesion. The microscopic examination revealed an undifferentiated tumor proliferation infiltrating the lymph node parenchyma. This tumor proliferation was INI1/SMARCB1-deficient, and expressed cytokeratins. Given the fact that the histopathological data showed an undifferentiated INI1-deficient carcinoma and that the patient has a kidney lesion and a sickle cell trait, the final diagnosis was lymph node metastasis of SMARCB1-deficient renal medullary carcinoma (OMS 2022)., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. [Fibro-osseous pseudotumor of the digits: An exemple of USP6-related fibroblastic/myofibroblastic tumor].
- Author
-
El Bejjaj I, Mercier A, Mcleer A, and Valmary-Degano S
- Subjects
- Humans, Female, Adult, Fingers pathology, Diagnosis, Differential, Myositis Ossificans pathology, Myositis Ossificans diagnosis, Ubiquitin Thiolesterase analysis
- Abstract
Fibro-osseous pseudotumor of the digits is a benign tumour closely related to myositis ossificans. It is a rare lesion seldom reported in the literature. We report the case of a 33-year-old woman with lancinating pain in the first phalanx of the second finger of the right hand, associated with inflammation. The histopathological examination of the surgical excision biopsy of the lesion revealed a spindle-shaped proliferation within a sclerosing, hyaline, and osteoid stroma. In our observation, immunohistochemistry and molecular biology are the main elements that helped to establish the diagnosis and eliminate the various differential diagnoses, despite a non-specific histopathological aspect., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms.
- Author
-
Benzerdjeb N, Dartigues P, Kepenekian V, Damiola F, Sequeiros R, Galateau-Salle F, Begueret H, Mery E, Damotte D, Verriele V, Fontaine J, Isaac S, Valmary-Degano S, Villeneuve L, Glehen O, Scherpereel A, Forest F, De la Fourchardiere A, Paindavoine S, Hourlier A, Pissaloux D, Tirode F, and Lantuejoul S
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Peritoneal Neoplasms genetics, Mesothelioma, Malignant genetics, Mesothelioma, Malignant pathology, Prognosis, Pleural Neoplasms genetics, Pleural Neoplasms pathology, Mesothelioma genetics, Mesothelioma pathology, Gene Fusion
- Abstract
Background: Mesothelioma is a rare and aggressive malignant neoplasm arising from mesothelial cells, which occasionally manifests recurrent fusions. EWSR1/FUS-CREB, YY1, MAP3K8, NR4A3, and ALK-rearranged proliferations have been reported in limited series with no clear histological or clinical correlations, limiting clinicians' ability to assess prognosis and integrate these new entities into therapeutic decisions. The aim of this study was to better characterize these rearranged proliferations histologically, molecularly, and clinically., Methods: Clinical, pathological, and comprehensive transcriptome and mutation data were collected for each case., Results: A total of 41 tumors were included, encompassing 7 ALK, 10 MAP3K8, 4 NR4A3, 8 ESWR1/FUS::ATF1, 8 EWSR1::YY1, and 4 SUFU-fused cases. We found a female predominance, except for cases harboring NR4A3 and SUFU; and most patients were around 60 years of age, but those harboring ALK or EWSR1/FUS::ATF1 gene fusions were younger. Each group exhibited distinct histological, immunohistochemical, molecular features, and oncological courses. Specifically, MAP3K8 and ALK presented PAX8+ papillary proliferations, ESWR1/FUS::ATF1 and EWSR1::YY1 displayed angiomatoid fibrous histiocytoma-like patterns, while SUFU showcased 'tissue culture'-like spindle cell proliferation. Poor prognosis factors were the pleural site, male sex, Ki67 ≥10%, and ESWR1/FUS::ATF1 or SUFU gene fusions., Conclusions: This study significantly broadens the spectrum of mesothelial tumors associated with fusions, offering insight into novel epithelioid (mesothelial) proliferations with distinctive histological appearances, molecular profiles, and prognoses to guide adapted treatments for patients., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. [Histoseminar tumoral peritoneal biopsies. Case No.1].
- Author
-
Valmary-Degano S
- Subjects
- Humans, Female, Biopsy, Diagnosis, Differential, Male, Middle Aged, Biomarkers, Tumor analysis, Peritoneal Neoplasms pathology, Peritoneal Neoplasms diagnosis
- Published
- 2024
- Full Text
- View/download PDF
26. [RENAPE network: Towards more equitable access to care and expertise for patients with rare peritoneal cancers].
- Author
-
Villeneuve L, Odin C, Bonnefoy I, Pichon P, Valmary-Degano S, and Bibeau F
- Subjects
- Humans, France, Peritoneal Neoplasms therapy, Peritoneal Neoplasms pathology, Health Services Accessibility, Rare Diseases therapy
- Abstract
Since its creation in 2010, the progressive structuration of the RENAPE network (Réseau national de prise en charge des tumeurs rares du péritoine) supported by the "Institut national du cancer" and the "Direction générale de l'offre de soins", allowed the optimization of the healthcare system involved in the management of the rare cancers of the peritoneum. In this setting, the RENA-PATH group has also been reinforced, notably by its recognized diagnostic expertise in pathology and its interface with the MESOPATH group. Moreover RENAPE and RENA-PATH led to guidelines diffusion through the integration, in 2019, to the ``Thesaurus National de Cancérologie Digestive'' (TNCD) and to post-university medical education programs. The aim of this article is to highlight the missions of the RENAPE and RENA-PATH, notably the equity in terms of expertise, access to the networks and their improvement in the management of peritoneal diseases., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF
27. [Histoseminar tumoral peritoneal biopsies. Introduction].
- Author
-
Benzerdjeb N, Dartigues P, Illac C, and Valmary-Degano S
- Subjects
- Humans, Biopsy, Peritoneal Neoplasms pathology, Peritoneal Neoplasms diagnosis
- Published
- 2024
- Full Text
- View/download PDF
28. Evaluation of immune infiltrate according to the HER2 status in colorectal cancer.
- Author
-
Molimard C, Dor F, Overs A, Monnien F, Gessain G, Kedochim L, D'Angelo F, Abad M, Heberle M, Derangère V, Ghiringhelli F, Vuitton L, Valmary-Degano S, Borg C, Lakkis Z, and Bibeau F
- Subjects
- Humans, Retrospective Studies, Female, Middle Aged, Male, Aged, Lymphocytes, Tumor-Infiltrating immunology, Adult, Microsatellite Instability, Aged, 80 and over, Colorectal Neoplasms genetics, Colorectal Neoplasms immunology, Colorectal Neoplasms pathology, Receptor, ErbB-2 metabolism, Receptor, ErbB-2 genetics, Immunohistochemistry, In Situ Hybridization, Fluorescence
- Abstract
Background and Aims: In colorectal cancer (CRC), HER2 targeting is a promising treatment and immune infiltrate is an important area of research and strategy. Data regarding HER2 status and immune infiltrate are lacking. The aim of this study was to compare the immune infiltrate between HER2 amplified and non-amplified categories in proficient MisMatchRepair (pMMR)/microsatellite stable (MSS) CRC., Methods: HER2 immunohistochemistry (IHC) and fluorescence in situ hybridization were performed in a retrospective series of 654 CRC. Lymphocyte infiltrate was analysed by anti-CD3, CD8 and CD4 IHC and evaluated digitally using QuPath software., Results: Among the 654 CRC, we first observed a decreased CD3+ and CD8+ infiltrate between HER2 amplified (all IHC 3+ except one 2+) and non-amplified HER2 2+ IHC CRC (p = 0.059 and 0.072 respectively). A supplementary analysis of 258 pMMR/MSS CRC from the previous cohort, displaying all the IHC scores (0, 1+, 2+, 3+), showed a lower CD3+ infiltrate between HER2 amplified versus HER2 0 (p = 0.002), 1+ (p = 0.088) and non-amplified 2+ (p = 0.081) IHC cases., Conclusions: Our original findings suggest that in pMMR/MSS CRC, the immune infiltrate is reduced in HER2 amplified versus other HER2 categories. These data might be useful for future strategies combining anti-HER2 treatments and immune checkpoint inhibitors and need to be confirmed in larger CRC cohorts., Competing Interests: Conflict of Interest Chloé Molimard, Fanny Dor, Alexis Overs, Franck Monnien, Grégoire Gessain, Loïs Kedochim, Flavia D'Angelo, Marine Abad, Morgane Heberle, Valentin Derangère, François Ghiringhelli, Lucine Vuitton, Séverine Valmary-Degano, Christophe Borg, Zaher Lakkis, Frédéric Bibeau have no competing financial interests of personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
29. [Renal synovialosarcoma: What about pyelic cytology to make a diagnosis?]
- Author
-
Da Silva F, Saada-Sebag G, Leer AM, Meilhac-Fournier C, Valmary-Degano S, and Giovannini D
- Subjects
- Female, Humans, Young Adult, Biopsy, Diagnosis, Differential, Nephrectomy, Urine cytology, Cytodiagnosis methods, Kidney Neoplasms pathology, Kidney Neoplasms diagnosis, Sarcoma, Synovial pathology, Sarcoma, Synovial diagnosis
- Abstract
Synovialosarcoma is a malignant mesenchymal tumor of young adults that occurs in the deep soft tissues, particularly around large joints. When it occurs in more unusual sites, it could present a significant diagnostic challenge. In this case, a 19-year-old girl was treated for a pyloric mass. A pyelic urine cytology performed simultaneously with a pyloric biopsy proved to be a significant element of orientation and perfectly concordant with the histopathological aspect of the pyelic mass after nephrectomy. We report here the first case of renal synovialosarcoma documented in pyelic urine., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. Amelioration of experimental autoimmune encephalomyelitis by in vivo reprogramming of macrophages using pro-resolving factors.
- Author
-
Gauthier T, Martin-Rodriguez O, Chagué C, Daoui A, Ceroi A, Varin A, Bonnefoy F, Valmary-Degano S, Couturier M, Behlke S, Saas P, Cartron PF, and Perruche S
- Subjects
- Animals, Neuroinflammatory Diseases, Macrophages, Inflammation, Leukocytes, Encephalomyelitis, Autoimmune, Experimental
- Abstract
Background: Reinstating inflammation resolution represents an innovative concept to regain inflammation control in diseases marked by chronic inflammation. While most therapeutics target inflammatory molecules and inflammatory effector cells and mediators, targeting macrophages to initiate inflammation resolution to control neuroinflammation has not yet been attempted. Resolution-phase macrophages are critical in the resolution process to regain tissue homeostasis, and are programmed through the presence and elimination of apoptotic leukocytes. Hence, inducing resolution-phase macrophages might represent an innovative therapeutic approach to control and terminate dysregulated neuroinflammation., Methods: Here, we investigated if the factors released by in vitro induced resolution-phase macrophages (their secretome) are able to therapeutically reprogram macrophages to control neuroinflammation in the model of experimental autoimmune encephalomyelitis (EAE)., Results: We found that injection of the pro-resolutive secretome reduced demyelination and decreased inflammatory cell infiltration in the CNS, notably through the in vivo reprogramming of macrophages at the epigenetic level. Adoptive transfer experiments with in vivo or in vitro reprogrammed macrophages using such pro-resolutive secretome confirmed the stability and transferability of this acquired therapeutic activity., Conclusions: Overall, our data confirm the therapeutic activity of a pro-resolution secretome in the treatment of ongoing CNS inflammation, via the epigenetic reprogramming of macrophages and open with that a new therapeutic avenue for diseases marked by neuroinflammation., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
31. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.
- Author
-
Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton NT, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Caliò A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard MP, Conde E, Copin MC, Côté JF, D'Haene N, Dai HY, de Leval L, Delongova P, Denčić-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin JL, Mertz KD, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti MG, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin JC, Salmon I, Prince SS, Scarpa A, Schuuring E, Serre I, Siozopoulou V, Sizaret D, Smojver-Ježek S, Solassol J, Steinestel K, Stojšić J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl SGF, Stenzinger A, and Ilié M
- Subjects
- Humans, Laboratories, Retrospective Studies, Pandemics, Mutation, ErbB Receptors genetics, Europe, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms diagnosis, Lung Neoplasms genetics, Lung Neoplasms pathology
- Abstract
Background: Testing for epidermal growth factor receptor (EGFR) mutations is an essential recommendation in guidelines for metastatic non-squamous non-small-cell lung cancer, and is considered mandatory in European countries. However, in practice, challenges are often faced when carrying out routine biomarker testing, including access to testing, inadequate tissue samples and long turnaround times (TATs)., Materials and Methods: To evaluate the real-world EGFR testing practices of European pathology laboratories, an online survey was set up and validated by the Pulmonary Pathology Working Group of the European Society of Pathology and distributed to 64 expert testing laboratories. The retrospective survey focussed on laboratory organisation and daily EGFR testing practice of pathologists and molecular biologists between 2018 and 2021., Results: TATs varied greatly both between and within countries. These discrepancies may be partly due to reflex testing practices, as 20.8% of laboratories carried out EGFR testing only at the request of the clinician. Many laboratories across Europe still favour single-test sequencing as a primary method of EGFR mutation identification; 32.7% indicated that they only used targeted techniques and 45.1% used single-gene testing followed by next-generation sequencing (NGS), depending on the case. Reported testing rates were consistent over time with no significant decrease in the number of EGFR tests carried out in 2020, despite the increased pressure faced by testing facilities during the COVID-19 pandemic. ISO 15189 accreditation was reported by 42.0% of molecular biology laboratories for single-test sequencing, and by 42.3% for NGS. 92.5% of laboratories indicated they regularly participate in an external quality assessment scheme., Conclusions: These results highlight the strong heterogeneity of EGFR testing that still occurs within thoracic pathology and molecular biology laboratories across Europe. Even among expert testing facilities there is variability in testing capabilities, TAT, reflex testing practice and laboratory accreditation, stressing the need to harmonise reimbursement technologies and decision-making algorithms in Europe., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
32. Should the artery be trimmed before anastomosis in every finger replantation/revascularization case? Prospective, single-center, multidisciplinary study over 46 months.
- Author
-
Pichonnat M, Buffet A, Monnien F, Aubry S, Pluvy I, Loisel F, Obert L, Valmary-Degano S, and Regas-Guerzider I
- Abstract
Introduction: Despite optimal arterial anastomosis, some finger replantations fail. Our objective was to evaluate how the mechanism of injury (MOI) affects the artery's microscopic appearance and the success of anastomosis. We hypothesized that the MOI influences arterial histology and microsurgical success., Methods: This single-center prospective study enrolled patients who had an acute traumatic arterial injury of the hand and/or wrist. The proximal and distal ends of the artery were trimmed before anastomosis in every case. The arterial margins were analyzed in anatomical pathology. Clinical follow-up along with an ultrasound arterial patency check was carried out at 1 month postoperative., Results: Between 2018 and 2022, 104 patients were enrolled with a follow-up of 12 months. Macroscopically, 42% of the arterial margins were dilapidated. Histological analysis found damage in 74% of surgical specimens: blast (100%)>laceration by mechanical or power tool (92%; 82%)>amputation by mechanical or power tool (80%; 67%)>laceration by glass (50%)>crush injury (33%). The arterial margins were more likely to be normal based on the histological analysis when the MOI was laceration by glass (p<.05; OR=3.72) and the patient was 65 years or older (p<.01). Risk factors for anastomosis failure were an amputation by power tool (p<.01, OR 8.19) and shorter length of arterial resection (p<.02). The clinical failure rate was 7.8% and the patency failure rate was 10.4%., Discussion: Histological arterial lesions correlate with the MOI. Trimming >2mm from the proximal and distal arterial ends is recommended for all MOI before arterial end-to-end anastomosis. For blast injuries or amputation, we recommend trimming>4mm and using a vein bypass graft. This study's findings could lead to a change in surgical practices., Level of Evidence: II; well-conducted non-randomized comparative study; recommendation grade B: scientific presumption., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
33. [Dasatinib-induced follicular lymphoid hyperplasia, an entity to know].
- Author
-
Phelippeau M, Lefebvre C, Jacob MC, Syrykh C, Ghelfi J, Carras S, Laurent C, Molina L, and Valmary-Degano S
- Subjects
- Humans, Dasatinib adverse effects, Hyperplasia chemically induced, Lymphoma, Follicular diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphadenopathy
- Abstract
Follicular lymphoid hyperplasia induced by dasatinib is an entity recently described. It is sometimes difficult to rule out the diagnostic of small B-cell lymphoma. Usually, the node is swollen, with follicular architecture conserved, composed by germinal centers with variable size and shape, with a hight number of mitoses and tingible bodies macrophages inside. Follicular lymphoid hyperplasia is isolated or associated with multiple reactive patterns. The immunohistochemical profil of germinal centers is CD20+, CD10+, BCL6+, BCL2-. Swollen node disappears in a short time after dasatinib discontinuation. Clinicians and pathologists need to be aware of this entity, so as not to avoid mistakenly suspect lymphoma when lymphadenopathy occurs in a patient with chronic myeloid leukemia treated with dasatinib., (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
34. Can AI predict epithelial lesion categories via automated analysis of cervical biopsies: The TissueNet challenge?
- Author
-
Loménie N, Bertrand C, Fick RHJ, Ben Hadj S, Tayart B, Tilmant C, Farré I, Azdad SZ, Dahmani S, Dequen G, Feng M, Xu K, Li Z, Prevot S, Bergeron C, Bataillon G, Devouassoux-Shisheboran M, Glaser C, Delaune A, Valmary-Degano S, and Bertheau P
- Abstract
The French Society of Pathology (SFP) organized its first data challenge in 2020 with the help of the Health Data Hub (HDH). The organization of this event first consisted of recruiting nearly 5000 cervical biopsy slides obtained from 20 pathology centers. After ensuring that patients did not refuse to include their slides in the project, the slides were anonymized, digitized, and annotated by expert pathologists, and finally uploaded to a data challenge platform for competitors from around the world. Competing teams had to develop algorithms that could distinguish 4 diagnostic classes in cervical epithelial lesions. Among the many submissions from competitors, the best algorithms achieved an overall score close to 95%. The final part of the competition lasted only 6 weeks, and the goal of SFP and HDH is now to allow for the collection to be published in open access for the scientific community. In this report, we have performed a "post-competition analysis" of the results. We first described the algorithmic pipelines of 3 top competitors. We then analyzed several difficult cases that even the top competitors could not predict correctly. A medical committee of several expert pathologists looked for possible explanations for these erroneous results by reviewing the images, and we present their findings here targeted for a large audience of pathologists and data scientists in the field of digital pathology., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
35. High-density lipoprotein infusion protects from acute graft-versus-host disease in experimental allogeneic hematopoietic cell transplantation.
- Author
-
Chagué C, Gautier T, Dal Zuffo L, Pais de Barros JP, Wetzel A, Tarris G, Pallot G, Martin L, Valmary-Degano S, Deckert V, Lagrost L, Daguindau E, and Saas P
- Subjects
- Acute Disease, Animals, CD8-Positive T-Lymphocytes, Lipopolysaccharides metabolism, Lipoproteins, HDL metabolism, Mice, Transplantation, Homologous, Graft vs Host Disease etiology, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods
- Abstract
Acute graft-versus-host disease (aGVHD) is a major limitation of the therapeutic potential of allogeneic hematopoietic cell transplantation. Lipopolysaccharides (LPS) derived from intestinal gram-negative bacteria are well-known aGVHD triggers and amplifiers. Here, we explored the LPS metabolism in aGVHD mouse models using an innovative quantification method. We demonstrated that systemic LPS accumulation after transplantation was due, at least partly, to a defect in its clearance through lipoprotein-mediated transport to the liver (i.e., the so-called reverse LPS transport). After transplantation, reduced circulating HDL concentration impaired LPS neutralization and elimination through biliary flux. Accordingly, HDL-deficient (Apoa1
tm1Unc ) recipient mice developed exacerbated aGVHD. Repeated administration of HDL isolated from human plasma significantly decreased the mortality and the severity of aGVHD. While the potential role of HDL in scavenging circulating LPS was examined in this study, it appears that HDL plays a more direct immunomodulatory role by limiting or controlling aGVHD. Notably, HDL infusion mitigated liver aGVHD by diminishing immune infiltration (e.g., interferon-γ-secreting CD8+ T cells and non-resident macrophages), systemic and local inflammation (notably cholangitis). Hence, our results revealed the interest of HDL-based therapies in the prevention of aGVHD., (© 2022 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.)- Published
- 2022
- Full Text
- View/download PDF
36. [The first data challenge of the french society of pathology: An international competition in 2020, a research tool in A.I. for the future?]
- Author
-
Delaune A, Valmary-Degano S, Loménie N, Zryouil K, Benyahia N, Trassard O, Eraville V, Bergeron C, Devouassoux-Shisheboran M, Glaser C, Bataillon G, Bacry E, Combes S, Prevot S, and Bertheau P
- Subjects
- Biopsy, Cervix Uteri, Female, Humans, Pathologists, Algorithms, Artificial Intelligence
- Abstract
The french society of pathology (SFP) organized in 2020 its first data challenge with the help of Health Data Hub (HDH). The organisation of this event first consisted in recruiting almost 5000 slides of uterus cervical biopsies obtained in 20 pathology centers. After having made sure that patients did not refuse to include their slides in the project, the slides were anonymised, digitized and annotated by expert pathologists, and were finally uploaded on a data challenge platform for competitors all around the world. Competitors teams had to develop algorithms that could distinguish among four diagnostic classes in epithelial lesions of uterine cervix. Among many submissions by competitors, the best algorithms obtained an overall score close to 95%. The best 3 teams shared 25k€ prizes during a special session organised during the national congress of the SFP. The final part of the competition lasted only 6 weeks and the goal of SFP and HDH is now to allow for the collection to be published in open access. This final step will allow data scientists and pathologists to further develop artificial intelligence algorithms in this medical area., (Copyright © 2021. Published by Elsevier Masson SAS.)
- Published
- 2022
- Full Text
- View/download PDF
37. A unilateral nasal obstruction.
- Author
-
Righini CA, Valmary-Degano S, and Fabre C
- Subjects
- Humans, Nasal Obstruction etiology
- Published
- 2022
- Full Text
- View/download PDF
38. Molecular diagnosis of alveolar echinococcosis in patients based on frozen and formalin-fixed paraffin-embedded tissue samples.
- Author
-
Knapp J, Lallemand S, Monnien F, Felix S, Valmary-Degano S, Courquet S, Demonmerot F, Heyd B, Turco C, Doussot A, Bourgeois L, Bresson-Hadni S, Richou C, and Millon L
- Subjects
- Animals, Formaldehyde, Humans, Paraffin Embedding, Real-Time Polymerase Chain Reaction, Echinococcosis diagnosis, Echinococcus multilocularis genetics
- Abstract
Confirmed diagnosis of alveolar echinococcosis (AE) is based on pathological criteria and molecular evidence. This parasite-borne disease, caused by the cestode Echinococcus multilocularis, sparingly involves humans as a dead-end host. In humans, the parasite mainly colonizes the liver but can colonize any organ and cause atypical forms, often difficult to characterize clinically. Moreover, molecular methods may be suitable to make the diagnosis of AE in cases of atypical forms, extra-hepatic localizations, or immunosuppressed patients. The aim of this study was to determine the most relevant published PCR techniques, for diagnosis of AE in patients and adopt the best strategy for molecular diagnosis depending on the nature of the tested sample. In this study, we evaluated nine end-point PCR assays and one real-time PCR assay (qPCR), targeting mitochondrial genes, using a total of 89 frozen or formalin-fixed paraffin-embedded (FFPE) samples from either 48 AE or 9 cystic echinococcosis patients. Targeted fragment-genes ranged from 84 to 529 bp. Six PCR assays were able to amplify the DNA of 100% of the frozen AE-samples and for one PCR, 69.8% of the FFPE AE-samples. The 16S rrnL PCR (84 bp) was positive in PCR for 77% of the AE samples and in qPCR for 86.5%. The sensitivity of the PCR assays was higher for fresh samples and FFPE samples stored for less than 5 years. The qPCR assay further increased sensitivity for the tested samples, confirming the need for the development of an Echinococcus spp. qPCR to improve the molecular diagnosis of echinococcoses., (© J. Knapp et al., published by EDP Sciences, 2022.)
- Published
- 2022
- Full Text
- View/download PDF
39. Pro-Resolving Factors Released by Macrophages After Efferocytosis Promote Mucosal Wound Healing in Inflammatory Bowel Disease.
- Author
-
Martin-Rodriguez O, Gauthier T, Bonnefoy F, Couturier M, Daoui A, Chagué C, Valmary-Degano S, Gay C, Saas P, and Perruche S
- Subjects
- Actins biosynthesis, Actins genetics, Animals, Biological Factors pharmacology, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes transplantation, Cell Division drug effects, Cell Line, Colitis chemically induced, Colitis etiology, Colitis immunology, DNA-Binding Proteins deficiency, Dextran Sulfate toxicity, Disease Models, Animal, Epithelial Cells drug effects, Epithelial Cells physiology, Female, Fibronectins biosynthesis, Fibronectins genetics, Humans, Inflammatory Bowel Diseases physiopathology, Inflammatory Bowel Diseases therapy, Intestinal Mucosa cytology, Intestinal Mucosa injuries, Lymphocyte Transfusion adverse effects, Mice, Mice, Inbred C57BL, Mice, Knockout, Specific Pathogen-Free Organisms, Biological Factors physiology, Cytophagocytosis physiology, Fibroblasts physiology, Inflammatory Bowel Diseases immunology, Macrophages physiology, Wound Healing physiology
- Abstract
Nonresolving inflammation is a critical driver of several chronic inflammatory diseases, including inflammatory bowel diseases (IBD). This unresolved inflammation may result from the persistence of an initiating stimulus or from the alteration of the resolution phase of inflammation. Elimination of apoptotic cells by macrophages (a process called efferocytosis) is a critical step in the resolution phase of inflammation. Efferocytosis participates in macrophage reprogramming and favors the release of numerous pro-resolving factors. These pro-resolving factors exert therapeutic effects in experimental autoimmune arthritis. Here, we propose to evaluate the efficacy of pro-resolving factors produced by macrophages after efferocytosis, a secretome called SuperMApo, in two IBD models, namely dextran sodium sulfate (DSS)-induced and T cell transfer-induced colitis. Reintroducing these pro-resolving factors was sufficient to decrease clinical, endoscopic and histological colitis scores in ongoing naive T cell-transfer-induced colitis and in DSS-induced colitis. Mouse primary fibroblasts isolated from the colon demonstrated enhanced healing properties in the presence of SuperMApo, as attested by their increased migratory, proliferative and contractive properties. This was confirmed by the use of human fibroblasts isolated from patients with IBD. Exposure of an intestinal epithelial cell (IEC) line to these pro-resolving factors increased their proliferative properties and IEC acquired the capacity to capture apoptotic cells. The improvement of wound healing properties induced by SuperMApo was confirmed in vivo in a biopsy forceps-wound colonic mucosa model. Further in vivo analysis in naive T cell transfer-induced colitis model demonstrated an improvement of intestinal barrier permeability after administration of SuperMApo, an intestinal cell proliferation and an increase of α-SMA expression by fibroblasts, as well as a reduction of the transcript coding for fibronectin ( Fn1 ). Finally, we identified TGF-β, IGF-I and VEGF among SuperMApo as necessary to favor mucosal healing and confirmed their role both in vitro (using neutralizing antibodies) and in vivo by depleting these factors from efferocytic macrophage secretome using antibody-coated microbeads. These growth factors only explained some of the beneficial effects induced by factors released by efferocytic macrophages. Overall, the administration of pro-resolving factors released by efferocytic macrophages limits intestinal inflammation and enhance tissue repair, which represents an innovative treatment of IBD., Competing Interests: FB, MC, PS, and SP are shareholders of MED’INN’Pharma SAS. FB, MC, and SP are employed by MED’INN’Pharma SAS which develops the SuperMApo biologic drug candidate. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Martin-Rodriguez, Gauthier, Bonnefoy, Couturier, Daoui, Chagué, Valmary-Degano, Gay, Saas and Perruche.)
- Published
- 2021
- Full Text
- View/download PDF
40. Combined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study.
- Author
-
Benzerdjeb N, Dartigues P, Kepenekian V, Valmary-Degano S, Mery E, Averous G, Chevallier A, Laverriere MH, Villa I, Sallé FG, Villeneuve L, Glehen O, Isaac S, and Hommell-Fontaine J
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biopsy, Female, France, Humans, Male, Mesothelioma, Malignant mortality, Mesothelioma, Malignant therapy, Middle Aged, Mitotic Index, Necrosis, Neoplasm Grading, Peritoneal Neoplasms mortality, Peritoneal Neoplasms therapy, Predictive Value of Tests, Progression-Free Survival, Registries, Retrospective Studies, Time Factors, Young Adult, Cell Nucleus pathology, Epithelioid Cells pathology, Mesothelioma, Malignant pathology, Peritoneal Neoplasms pathology
- Abstract
Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. A recently described nuclear-grading system predicted survival in patients with epithelioid malignant pleural mesothelioma. The present study was undertaken to validate this grading system in epithelioid malignant peritoneal mesothelioma (EMPM) and to compare to combined grade, including nuclear atypia, mitotic count, and tumor necrosis. Cases of EMPM, from 1995 to 2018, were analyzed from 7 French institutions from RENAPE network. Solid growth, tumor necrosis, nuclear atypia, and mitotic count were evaluated by at least 3 pathologists from the RENAPATH group. The predictions in terms of OS and PFS of nuclear grade and combined grade were analyzed. Nuclear grade was computed combining nuclear atypia score and mitotic count into a grade of I-III. Another system combining nuclear atypia score, mitotic score, and tumor necrosis was evaluated and defined as a combined grade I-III. A total of 138 cases were identified. The median follow-up was 38.9 months (range: 1.1-196.6). Nuclear and combined grades III were independently associated with a shorter OS (p < 0.05), and a shorter PFS (p < 0.05). Patients with combined grade I tumors had the best overall and progression-free survivals, in comparison to nuclear grade I. In this large multicentric study, combined grade and nuclear grade were the best independent predictors of OS and PFS in EMPM. These systems should be easily described by pathologists involved into the management of malignant peritoneal mesothelioma, because of their potential therapeutic implications., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
41. Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis.
- Author
-
Benzerdjeb N, Dartigues P, Kepenekian V, Valmary-Degano S, Mery E, Avérous G, Chevallier A, Laverriere MH, Villa I, Harou O, Sallé FG, Villeneuve L, Glehen O, Isaac S, Hommell-Fontaine J, and Bibeau F
- Subjects
- Adult, Aged, Aged, 80 and over, Female, France epidemiology, Humans, Lung Neoplasms pathology, Lymph Nodes pathology, Male, Mesothelioma pathology, Mesothelioma, Malignant metabolism, Middle Aged, Neoadjuvant Therapy methods, Peritoneal Neoplasms metabolism, Peritoneal Neoplasms mortality, Peritoneum pathology, Prognosis, Retrospective Studies, Tumor Microenvironment, Mesothelioma, Malignant pathology, Peritoneal Neoplasms pathology, Tertiary Lymphoid Structures pathology
- Abstract
Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. The relationship between a strong adaptive immune response and a better prognosis in malignant solid tumors is widely known. Due to the low incidence of epithelioid malignant peritoneal mesothelioma (EMPM), very little is known about their immune micro-environment. We encountered several cases of tertiary lymphoid structures in EMPM in a previous study and aimed to investigate in the same series the prevalence, clinicopathological features, and the prognostic impact associated with tertiary lymphoid structures in EMPM (TLS-EMPM). Cases of EMPM, from 1995 to 2018, were retrieved from 7 French institutions from the RENAPE Network. The predictions in terms of overall survival (OS) and progression-free survival (PFS) of TLS-EMPM were analyzed. We report 52 cases of TLS-EMPM among a series of 138 cases of EMPM. TLS-EMPM was significantly associated with neoadjuvant chemotherapy, and was not a prognostic indicator for OS (p = 0.652) and PFS (p = 0.804) in our series. TLS is a component of the host immune response to EMPM significantly associated with neoadjuvant chemotherapy, but was not a predictor of prognosis for overall and progression-free survivals in this series. These findings provide another possible etiology for tertiary lymphoid structures., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
42. HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study.
- Author
-
Baumann A, Henriques J, Selmani Z, Meurisse A, Lepiller Q, Vernerey D, Valmary-Degano S, Paget-Bailly S, Riethmuller D, Ramanah R, Mougin C, and Prétet JL
- Abstract
High-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous countries. However, there is still a need for relevant triage strategies to manage hrHPV positive women to avoid excessive referral to colposcopy. The objective of this study was to assess, in women infected by hrHPV and presenting no or mild cytological abnormalities, HPV16 and HPV18 viral loads to predict the development of cervical high-grade lesion. Among 2102 women positive for hrHPV, 885 had no lesion or mild cytological abnormalities at baseline and had at least one follow-up (FU) visit. HPV16 and HPV18 prevalence was 25.9% and 8.4%, respectively. Of those women, 15% developed a high-grade lesion during the FU. An HPV16 viral load cut-off set at 3.2 log
10 GE/103 cells permitted to identify a subgroup of women at high risk of developing high-grade cervical lesion (HR = 2.67; 95% CI 1.80-3.97; p ≤ 0.0001). No specific HPV18 viral load threshold could have been defined in regard to the present study. In multivariate analysis, HPV16 load (absence/log10 GE/103 cells < 3.2 vs. ≥3.2), RLU/PC 239 (1-100 pg/mL vs. >100 pg/mL) and cytology (normal vs abnormal) were independently associated with a significant increased risk of high-grade lesion development and were used to construct the prognostic score. In conclusion, HPV16 load is a relevant biomarker to identify women at high risk for developing cervical precancerous lesions.- Published
- 2021
- Full Text
- View/download PDF
43. Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma.
- Author
-
Claves F, Siest R, Lefebvre C, Valmary-Degano S, and Carras S
- Subjects
- Adenine therapeutic use, Female, Humans, Interleukin-1 genetics, Middle Aged, Adenine analogs & derivatives, Lymphoma drug therapy, Piperidines therapeutic use, Schnitzler Syndrome drug therapy
- Published
- 2021
- Full Text
- View/download PDF
44. Thoracic NUT carcinoma: Common pathological features despite diversity of clinical presentations.
- Author
-
Fekkar A, Emprou C, Lefebvre C, Ferretti G, Stephanov O, Pissaloux D, Mc Leer A, Toffart AC, Rousseaux S, Khochbin S, Lantuejoul S, and Valmary-Degano S
- Subjects
- Cell Cycle Proteins, Humans, Male, Nuclear Proteins genetics, Oncogene Proteins, Transcription Factors, Carcinoma diagnosis, Carcinoma genetics, Carcinoma therapy, Lung Neoplasms
- Abstract
NUT carcinoma (NC), formerly known as NUT midline carcinoma, is a rare and very aggressive cancer. It is genetically defined by the presence of acquired chromosomal rearrangement of the NUTM1 (NUclear protein in Testis Midline carcinoma family member 1) gene at chromosome 15q14 with a member of the bromodomain-containing protein (BRD) family gene, usually BRD4. Although primarily reported in the head and neck, and mediastinum locations of younger individuals, it is now established that NC arises in multiple sites in patients of all ages, with no gender predilection. NC is very likely to be underdiagnosed because of a lack of awareness of both clinicians and pathologists on the one hand, and of a nonspecific histological presentation on the other hand. As it is indistinguishable from other poorly differentiated carcinomas, pathologists should consider NC as a differential diagnosis of any poorly differentiated tumour. Diagnosis is now easily made by immunohistochemistry, using a highly sensitive and specific NUT monoclonal antibody. Despite chemo- or chemo-radiotherapy, the prognosis of this tumour remains very poor. We report here a series of 3 cases of NC with different clinical and pathological presentations in order to draw attention on some common morphological features that can help clinicians and pathologists to think about this rare entity., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
45. Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies.
- Author
-
Bussot L, Chevalier S, Cristante J, Grange B, Tesson B, Deteix-Santana C, Orsini-Piocelle F, Leyronnas C, Dupire S, Gressin R, Salles G, Bachy E, Emadali A, Valmary-Degano S, Huet S, Lefebvre C, and Carras S
- Subjects
- Adult, Aged, Aged, 80 and over, Gene Duplication, Humans, Lymphoma, Follicular diagnosis, Lymphoma, Follicular therapy, Middle Aged, Prognosis, Progression-Free Survival, Retrospective Studies, Young Adult, Gene Rearrangement, Lymphoma, Follicular genetics, Proto-Oncogene Proteins c-myc genetics
- Abstract
Follicular lymphomas (FLs) with MYC rearrangements (MYC-R) and extra copies of MYC (MYC-EC) are rare and the prognosis impact is uncertain. We conducted a retrospective study including 321 FL patients, among whom 259 (81%) had no 8q24 alterations and 62 (19%) were assigned to 8qAlt. Forty-five cases were classified as MYC-EC and six as MYC-R. MYC-R patients were significantly older (P = 0·008), had higher follicular lymphoma international prognostic index (FLIPI) stage (P = 0·05) and β2-microglobulin (β2m; P = 0·05). Among patients treated with immuno-chemotherapy, four presented a MYC-R and 25 a MYC-EC. Univariate analysis showed the absence of significant difference between MYC-EC and normal MYC (MYC-NL) regarding progression-free survival (PFS; HR1·3; 95% CI [0·4-1·6]) and specific overall survival (SOS; HR 1·6; 95% CI [0·4-5·7]). Those results were compared to data from the PRIMA trial. This confirmed that MYC-EC had no impact on PFS (P = 0·86) or SOS (P = 0·9). Conversely, MYC-R was associated with a trend to inferior outcome regarding PFS (HR : 6·1; 95% CI [2·2-17·1]; P = 0·00026), lymphoma-related death (SOS; HR 13·6; 95% CI [2·9-65]; P = 0·00014) and risk of transformation (transformation-free survival (TFS); HR 82·7; 95% CI [14·8-463·4]; P < 0·0001). In conclusion, MYC-EC has no prognostic impact in FL but MYC-R FL tended to be associated with an increased risk of transformation and poorer outcome., (© 2021 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
46. [Primary liposarcomas of the digestive tract: Diversity of clinicopathological presentations and diagnostic challenges].
- Author
-
Fekkar A, Mc Leer A, Chapuis P, Brichon PY, Chirica M, Laramas M, and Valmary-Degano S
- Subjects
- Adult, Gastrointestinal Tract, Humans, Liposarcoma diagnosis, Sarcoma, Soft Tissue Neoplasms
- Abstract
Sarcomas are rare tumours that represent less than 1% of all malignant tumours in adults. Liposarcomas are among the most common malignant mesenchymal tumours. They are preferentially located in the limbs and the retroperitoneum. Liposarcomas primarily arising in the digestive tract are exceptional with a few cases reported in the literature. Their clinical presentation is variable and the symptoms are not specific. Anatomopathological examination remains the gold standard for the diagnosis and the classification of these tumours, which are divided into 5 histological types according to the 5th edition of the WHO classification of soft tissue tumours. We report two observations of unusual digestive liposarcomas, located in the oesophagus and the colon, emphasizing the variability of the diagnostic challenges, depending on the clinical presentation, the histological type and the analysed material., (Copyright © 2021 Elsevier Masson SAS. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
47. Peritoneal or mesenteric tumours revealing histiocytosis.
- Author
-
Cohen-Aubart F, Ungureanu I, Razanamahery J, Charlotte F, Valmary-Degano S, Hélias-Rodzewicz Z, Cazals-Hatem D, Dartigues P, Delage-Corre M, Selves J, Tas P, Humbert S, Malakhia A, Kunnamo M, Veresezan L, Prokopiou C, Seeber A, Tazi A, Donadieu J, Lucidarme O, Haroche J, and Emile JF
- Subjects
- Delayed Diagnosis, Humans, Proto-Oncogene Proteins B-raf genetics, Retrospective Studies, Histiocytosis, Neoplasms
- Abstract
Objective: Peritoneal or mesenteric tumours may correspond to several tumour types or tumour-like conditions, some of them being represented by histiocytosis. This rare condition often poses diagnostic difficulties that can lead to important time delay in targeted therapies. Our aim was to describe main features of histiocytoses with mesenteric localisation that can improve the diagnostic process., Design: We performed a retrospective study on 22 patients, whose peritoneal/mesenteric biopsies were infiltrated by histiocytes., Results: Abdominal pain was the revealing symptom in 10 cases, and 19 patients underwent surgical biopsies. The diagnosis of histiocytosis was proposed by initial pathologists in 41% of patients. The other initial diagnoses were inflammation (n=7), sclerosing mesenteritis (n=4) and liposarcoma (n=1). The CD163/CD68+CD1a- histiocytes infiltrated subserosa and/or deeper adipose tissues in 16 and 14 cases, respectively. A BRAF
V600E mutation was detected within the biopsies in 11 cases, and two others were MAP2K1 mutated. The final diagnosis was histiocytosis in 18 patients, 15 of whom had Erdheim-Chester disease. The median diagnostic delay of histiocytosis was 9 months. Patients treated with BRAF or MEK inhibitors showed a partial response or a stable disease. One patient died soon after surgery, and five died by the progression of the disease., Conclusion: Diagnosis of masses arising in the mesentery should be carefully explored as one of the possibilities in histiocytosis. This diagnosis is frequently missed on mesenteric biopsies. Molecular biology for detecting the mutations in BRAF or in genes of the MAP kinase pathway is a critical diagnostic tool., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2021
- Full Text
- View/download PDF
48. Treatment algorithm and prognostic factors for patients with stage I-III carcinoma of the anal canal: a 20-year multicenter study.
- Author
-
Bruyere D, Monnien F, Colpart P, Roncarati P, Vuitton L, Hendrick E, Lepinoy A, Luquain A, Pilard C, Lerho T, Molimard C, Maingon P, Arnould L, Bone-Lepinoy MC, Dusserre L, Martin L, Reynders C, Ancion M, Peiffert D, Leroux A, Hubert P, Delhorme JB, Ghnassia JP, Woronoff AS, Delvenne P, Prétet JL, Bosset JF, Peulen O, Mougin C, Valmary-Degano S, and Herfs M
- Subjects
- Adult, Aged, Anus Neoplasms epidemiology, Carcinoma, Squamous Cell epidemiology, Female, Humans, Incidence, Male, Middle Aged, Prognosis, Progression-Free Survival, Treatment Outcome, Algorithms, Anus Neoplasms pathology, Anus Neoplasms therapy, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell therapy
- Abstract
Despite a growing incidence in developed countries and a recent improved understanding of its pathogenesis, anal cancer management has not evolved over the past decades and drug combination used as first-line regimen still largely depends on clinician preferences. Aiming at paving the way for precision medicine, a large cohort of 372 HIV-negative patients diagnosed over a 20-year time period with locally advanced anal carcinoma was collected and carefully characterized at the clinical, demographic, histopathologic, immunologic, and virologic levels. Both the prognostic relevance of each clinicopathological parameter and the efficacy of different concurrent chemoradiation strategies were determined. Overall, the incidence of anal cancer peaked during the sixth decade (mean: 63.4) and females outnumbered males (ratio: 2.51). After completion of treatment, 95 (25.5%) patients experienced progression of persistent disease or local/distant recurrence and 102 (27.4%) died during the follow-up period (median: 53.8 months). Importantly, uni-multivariate analyses indicated that both negative HPV/p16
ink4a status and aberrant p53 expression were far better predictors for reduced progression-free survival than traditional risk factors such as tumor size and nodal status. As for overall survival, the significant influences of age at diagnosis, p16ink4a status, cTNM classification as well as both CD3+ and CD4+ T-cell infiltrations within tumor microenvironment were highlighted. Cisplatin-based chemoradiotherapy was superior to both radiotherapy alone and other concurrent chemoradiation therapies in the treatment of HPV-positive tumors. Regarding their HPV-uninfected counterparts, frequent relapses were observed, whatever the treatment regimen administered. Taken together, our findings reveal that current anal cancer management and treatment have reached their limits. A dualistic classification according to HPV/p53 status should be considered with implications for therapy personalization and optimization.- Published
- 2021
- Full Text
- View/download PDF
49. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.
- Author
-
Bôle-Richard E, Fredon M, Biichlé S, Anna F, Certoux JM, Renosi F, Tsé F, Molimard C, Valmary-Degano S, Jenvrin A, Warda W, Pallandre JR, Bonnefoy F, Poussard M, Deschamps M, Petrella T, Roumier C, Macintyre E, Féger F, Brissot E, Mohty M, HoWangYin KY, Langlade-Demoyen P, Loustau M, Caumartin J, Godet Y, Binda D, Pagadoy M, Deconinck E, Daguindau E, Saas P, Ferrand C, Angelot-Delettre F, Adotévi O, and Garnache-Ottou F
- Subjects
- Animals, Cell Line, Tumor, Cytotoxicity, Immunologic immunology, HL-60 Cells, Hematologic Neoplasms immunology, Humans, Immunotherapy, Adoptive methods, Mice, CD28 Antigens immunology, Dendritic Cells immunology, Interleukin-3 Receptor alpha Subunit immunology, T-Lymphocytes immunology
- Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is associated with a remarkably poor prognosis and with no treatment consensus. The identification of relevant therapeutic targets is challenging. Here, we investigated the immune functions, antileukemia efficacy and safety of CD28/4-1BB CAR T cells targeting CD123 the interleukin (IL)-3 receptor alpha chain which is overexpressed on BPDCN. We demonstrated that both retroviral and lentiviral engineering CD28/4-1BB CD123 CAR T cells exhibit effector functions against BPDCN cells through CD123 antigen recognition and that they efficiently kill BPDCN cell lines and BPDCN-derived PDX cells. In vivo, CD28/4-1BB CD123 CAR T-cell therapy displayed strong efficacy by promoting a decrease of BPDCN blast burden. Furthermore we showed that T cells from BPDCN patient transduced with CD28/4-1BB CD123 CAR successfully eliminate autologous BPDCN blasts in vitro. Finally, we demonstrated in humanized mouse models that these effector CAR T cells exert low or no cytotoxicity against various subsets of normal cells with low CD123 expression, indicating a potentially low on-target/off-tumor toxicity effect. Collectively, our data support the further evaluation for clinical assessment of CD28/4-1BB CD123 CAR T cells in BPDCN neoplasm.
- Published
- 2020
- Full Text
- View/download PDF
50. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
- Author
-
Baltres A, Al Masry Z, Zemouri R, Valmary-Degano S, Arnould L, Zerhouni N, and Devalland C
- Subjects
- Adult, Aged, Aged, 80 and over, Breast pathology, Breast Neoplasms epidemiology, Breast Neoplasms pathology, Breast Neoplasms therapy, Female, Follow-Up Studies, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local pathology, Prognosis, ROC Curve, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Retrospective Studies, Supervised Machine Learning, Biomarkers, Tumor genetics, Breast Neoplasms genetics, Models, Genetic, Neoplasm Recurrence, Local epidemiology
- Abstract
Oncotype DX (ODX) is a multi-gene expression signature designed for estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients to predict the recurrence score (RS) and chemotherapy (CT) benefit. The aim of our study is to develop a prediction tool for the three RS's categories based on deep multi-layer perceptrons (DMLP) and using only the morphoimmunohistological variables. We performed a retrospective cohort of 320 patients who underwent ODX testing from three French hospitals. Clinico-pathological characteristics were recorded. We built a supervised machine learning classification model using Matlab software with 152 cases for the training and 168 cases for the testing. Three classifiers were used to learn the three risk categories of the ODX, namely the low, intermediate, and high risk. Experimental results provide the area under the curve (AUC), respectively, for the three risk categories: 0.63 [95% confidence interval: (0.5446, 0.7154), p < 0.001], 0.59 [95% confidence interval: (0.5031, 0.6769), p < 0.001], 0.75 [95% confidence interval: (0.6184, 0.8816), p < 0.001]. Concordance rate between actual RS and predicted RS ranged from 53 to 56% for each class between DMLP and ODX. The concordance rate of low and intermediate combined risk group was 85%.We developed a predictive machine learning model that could help to define patient's RS. Moreover, we integrated histopathological data and DMLP results to select tumor for ODX testing. Thus, this process allows more relevant use of histopathological data, and optimizes and enhances this information.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.